Harvard Bioscience
HBIO
64 hedge funds and large institutions have $11.7M invested in Harvard Bioscience in 2025 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 15 reducing their positions, and 8 closing their positions.
1,240% more call options, than puts
Call options by funds: $67K | Put options by funds: $5K
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
60% more capital invested
Capital invested by funds: $7.29M → $11.7M (+$4.39M)
33% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 15
7% more funds holding
Funds holding: 60 → 64 (+4)
0.18% more ownership
Funds ownership: 3.73% → 3.92% (+0.18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Corsair Capital Management
New York
|
+$598K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$417K |
| 3 |
Two Sigma Advisers
New York
|
+$377K |
| 4 |
Two Sigma Investments
New York
|
+$319K |
| 5 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$243K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Harvey Partners
Tarrytown,
New York
|
-$899K |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$278K |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$265K |
| 4 |
AI
Acuitas Investments
Seattle,
Washington
|
-$215K |
| 5 |
PPW
Pasadena Private Wealth
Pasadena,
California
|
-$118K |
HBIO Hedge Fund Activity: Q4 2025 in Review
64 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q4 2025, worth a combined $11.7M — up 60% from $7.29M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new HBIO positions and 8 closed out — a net gain of 6 holders — while 20 added to existing stakes and 15 trimmed.
The largest buyer was Corsair Capital Management, adding an estimated $598K. The largest seller was Harvey Partners, exiting entirely with an estimated $899K sold.
- 64 institutional investors held Harvard Bioscience (HBIO) as of Q4 2025, up from 60 in Q3 2025.
- Funds reported $11.7M of Harvard Bioscience stock for Q4 2025, up 60% quarter-over-quarter.
- 14 funds opened new Harvard Bioscience positions in Q4 2025 and 8 closed out, a net change of +6 holders.
- The largest Harvard Bioscience buyer in Q4 2025 was Corsair Capital Management, an estimated $598K added.
- The largest Harvard Bioscience seller in Q4 2025 was Harvey Partners, an estimated $899K sold.
Based on aggregated 13F filings for Q4 2025.